Mannose-Binding Lectin (Protein C) 2, Soluble (MBL2) Antikörper

Antigen: Mannose-Binding Lectin (Protein C) 2, Soluble (MBL2)

Synonyme: MBL, MBP, MBP1, COLEC1, HSMBPC, MGC116832, MGC116833, MBP-C, pMBP-27, MBL2, mbl2

Klonalität: Polyklonal

Wirt: Ziege

Reaktivität: Human

Applikation: ELISA, Western Blot (WB)

Produktnummer: ABIN185321

Produktbeschreibung

Weitere Bezeichnung: MBL2 / Mannan-Binding Lectin

Gen-ID: 4153

Immunogen: STSHLAVCEFPI

Format: Affinity-purified

Beschreibung: All names and symbols: MBL2, mannan-binding lectin, MBL, MBP, MBP1, COLEC1, HSMBPC, mannose-binding lectin (protein C) 2, soluble (opsonic defect), mannan-binding protein, mannose binding protein, Mannose-binding lectin 2, soluble (opsonic defect). Official Symbol: MBL2. RefSeq number(s): NP_000233. Gene ontology terms: complement activation, classical pathway, complement activation, lectin pathway, cytoplasm, extracellular space, immune response, mannose binding, membrane, phosphate transport, receptor binding, response to oxidative stress, sugar binding

Spezifität: Human, Chimpanzee 248 aa

Anwendungen

Applikationshinweise: Peptide ELISA: antibody detection limit dilution 1:4,000. Western Blot: Approx 26kDa band observed in Human Heart and Human Kidney lysates (calculated MW of 26.1kDa according to NP_000233). Recommended concentration: 1-3µg/ml.

Reinigung: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Buffer: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Lagerung: Aliquot and store at -20°C. Minimize freezing and thawing.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

ABIN185321 (1µg/ml) staining of Human Heart lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Publikationen

Publikationen: Saevarsdottir, Oskarsson, Aspelund et al.: "Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk." in: The Journal of experimental medicine, Vol. 201, Issue 1, pp. 117-25, 2005 (PubMed).